However, when testing combinations of PARP inhibitor and temozolomide in D425 and D384, both Group 3 models, p53 status does not predict PARP inhibitor response, and in fact D425, a TP53 mutant model, tumor growth inhibition is greater compared to D384 and D283 from the same study (61). This evidence concerns the gene TP53 and neoplasm.